{"name":"Promomed, LLC","slug":"promomed-llc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"neuroscience","drugs":[{"name":"metformin+sibutramine","genericName":"metformin+sibutramine","slug":"metformin-sibutramine","indication":"Type 2 diabetes mellitus with obesity","status":"marketed"},{"name":"sibutramine+ microcrystalline cellulose","genericName":"sibutramine+ microcrystalline cellulose","slug":"sibutramine-microcrystalline-cellulose","indication":"Obesity management in patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with comorbidities","status":"marketed"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Double-Stranded RNA sodium salt","genericName":"Double-Stranded RNA sodium salt","slug":"double-stranded-rna-sodium-salt","indication":"Cancer immunotherapy (specific indications in phase 3 trials not publicly detailed)","status":"phase_3"}]},{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Ethyl methyl hydroxypyridine succinate + Meldonium","genericName":"Ethyl methyl hydroxypyridine succinate + Meldonium","slug":"ethyl-methyl-hydroxypyridine-succinate-meldonium","indication":"Acute myocardial infarction","status":"marketed"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"Molnupiravir (Esperavir)","genericName":"Molnupiravir (Esperavir)","slug":"molnupiravir-esperavir","indication":"COVID-19 (treatment of mild to moderate disease in adults at high risk of progression)","status":"phase_3"}]}],"pipeline":[{"name":"Double-Stranded RNA sodium salt","genericName":"Double-Stranded RNA sodium salt","slug":"double-stranded-rna-sodium-salt","phase":"phase_3","mechanism":"Double-stranded RNA activates pattern recognition receptors on immune cells to stimulate innate and adaptive immune responses against tumors.","indications":["Cancer immunotherapy (specific indications in phase 3 trials not publicly detailed)"],"catalyst":""},{"name":"Ethyl methyl hydroxypyridine succinate + Meldonium","genericName":"Ethyl methyl hydroxypyridine succinate + Meldonium","slug":"ethyl-methyl-hydroxypyridine-succinate-meldonium","phase":"marketed","mechanism":"This combination product enhances cellular energy metabolism and reduces oxidative stress through antioxidant and cardioprotective mechanisms.","indications":["Acute myocardial infarction","Chronic heart failure","Cerebrovascular disease","Angina pectoris"],"catalyst":""},{"name":"Molnupiravir (Esperavir)","genericName":"Molnupiravir (Esperavir)","slug":"molnupiravir-esperavir","phase":"phase_3","mechanism":"Molnupiravir is a nucleoside analog that induces viral mutagenesis by causing errors during viral RNA replication, leading to viral extinction.","indications":["COVID-19 (treatment of mild to moderate disease in adults at high risk of progression)","Influenza (investigational)"],"catalyst":""},{"name":"metformin+sibutramine","genericName":"metformin+sibutramine","slug":"metformin-sibutramine","phase":"marketed","mechanism":"Metformin reduces hepatic glucose production and improves insulin sensitivity, while sibutramine suppresses appetite by inhibiting reuptake of serotonin and norepinephrine, together addressing hyperglycemia and weight management in type 2 diabetes.","indications":["Type 2 diabetes mellitus with obesity"],"catalyst":""},{"name":"sibutramine+ microcrystalline cellulose","genericName":"sibutramine+ microcrystalline cellulose","slug":"sibutramine-microcrystalline-cellulose","phase":"marketed","mechanism":"Sibutramine inhibits the reuptake of norepinephrine, serotonin, and dopamine in the central nervous system, increasing satiety and reducing appetite.","indications":["Obesity management in patients with BMI ≥30 kg/m² or BMI ≥27 kg/m² with comorbidities"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOS3BIbDQtVG40Y2VTVWY3TzJSdVFYRUpjUVhVYkw4c2V5ZVRhejJ6clUtVFN6NTVSX1pacS0yUTIyNnJoZFVuMkpsd1h1NlJPTDFkU3pRcS1RVy0tYjNuNXJJMExJemFvQkFJVzlSelIwZUFudUVxcGJiLVR0T092ZVNnTlo3aHBMZXlKc1l5X3pfcW40aEtYcUViM3EyMTNhWDRwQ0haYkMyWU1jMnZJOdIBsAFBVV95cUxOS3BIbDQtVG40Y2VTVWY3TzJSdVFYRUpjUVhVYkw4c2V5ZVRhejJ6clUtVFN6NTVSX1pacS0yUTIyNnJoZFVuMkpsd1h1NlJPTDFkU3pRcS1RVy0tYjNuNXJJMExJemFvQkFJVzlSelIwZUFudUVxcGJiLVR0T092ZVNnTlo3aHBMZXlKc1l5X3pfcW40aEtYcUViM3EyMTNhWDRwQ0haYkMyWU1jMnZJOQ?oc=5","date":"2026-01-12","type":"regulatory","source":"Новости GxP","summary":"Two more Russian pharma companies granted permission to use semaglutide patents - Новости GxP","headline":"Two more Russian pharma companies granted permission to use semaglutide patents - Новости GxP","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_3":2,"marketed":3},"enrichmentLevel":0,"visitCount":5,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}